← All trials
NCT04456595
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 21, 2020
- Primary completion
- Sep 30, 2021
- Completion date
- Oct 31, 2021
- First posted
- Jul 2, 2020
- Last posted
- Dec 11, 2020
- Enrollment
- 13060
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Butantan InstituteLead sponsor
- Butantan InstituteStudy director
- China National Pharmaceutical GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.